Response to treatment with CHOP-21, CHOP-14, CHOEP-21, and CHOEP-14
. | CHOP-21 . | CHOP-14 . | CHOEP-21 . | CHOEP-14 . |
|---|---|---|---|---|
| Complete response | ||||
| n (%) | 107 (60.1) | 131 (76.1) | 119 (70.0) | 121 (71.6) |
| 95% Cl, % (lower limit; upper limit) | (52.5; 67.4) | (69.1; 82.3) | (62.5; 76.8) | (64.2; 78.3) |
| Partial response | ||||
| n (%) | 5 (2.8) | 11 (6.4) | 10 (5.9) | 11 (6.5) |
| 95% Cl, % (lower limit; upper limit) | (0.9; 6.4) | (3.2; 11.2) | (2.9; 10.6) | (3.3; 11.4) |
| Stable disease | ||||
| n (%) | 2 (1.1) | 1 (0.6) | 2 (1.2) | 1 (0.6) |
| 95% Cl, % (lower limit; upper limit) | (0.1; 4.0) | (0.0; 3.2) | (0.1; 4.2) | (0.0; 3.2) |
| Progression under treatment* | ||||
| n (%) | 52 (29.2) | 20 (11.6) | 25 (14.7) | 16 (9.5) |
| 95% Cl, % (lower limit; upper limit) | (22.6; 36.5) | (7.2; 17.4) | (9.8; 20.9) | (5.5; 14.9) |
| Therapy-associated deaths without progression | ||||
| n (%) | 6 (3.4) | 5 (2.9) | 9 (5.3) | 13 (7.7) |
| 95% Cl, % (lower limit; upper limit) | (1.2; 7.2) | (1.0; 6.6) | (2.4; 9.8) | (4.2; 12.8) |
| Unknown | ||||
| n (%) | 0 (0.0) | 1 (0.6) | 2 (1.2) | 4 (2.4) |
| 95% Cl, % (lower limit; upper limit) | (0.0; 2.0) | (0.0; 3.2) | (0.1; 4.2) | (0.6; 6.0) |
| Additional therapy† | ||||
| n (%) | 6 (3.4) | 3 (1.8) | 3 (1.8) | 3 (1.8) |
| 95% Cl, % (lower limit; upper limit) | (1.2; 7.2) | (0.4; 5.0) | (0.4; 5.1) | (0.4; 5.1) |
| 3-year EFS | ||||
| % patients | 41.3 | 54.2 | 45.5 | 46.0 |
| 95% Cl, % (lower limit; upper limit) | (33.9; 48.6) | (46.6; 61.8) | (37.9; 53.2) | (38.3; 53.6) |
| 5-year EFS‡ | ||||
| % patients | 32.5 | 43.8 | 41.1 | 40.2 |
| 95% Cl, % (lower limit; upper limit) | (24.7; 40.3) | (35.4; 52.1) | (33.2; 48.9) | (32.2; 48.2) |
| 3-year overall survival | ||||
| % patients | 48.8 | 68.5 | 57.7 | 56.4 |
| 95% Cl, % (lower limit; upper limit) | (41.1; 56.4) | (61.3; 75.6) | (50.1; 65.3) | (48.6; 64.1) |
| 5-year overall survival‡ | ||||
| % patients | 40.6 | 53.3 | 45.8 | 49.8 |
| 95% Cl, % (lower limit; upper limit) | (32.5; 48.6) | (44.6; 62.1) | (37.4; 54.2) | (41.5; 58.0) |
. | CHOP-21 . | CHOP-14 . | CHOEP-21 . | CHOEP-14 . |
|---|---|---|---|---|
| Complete response | ||||
| n (%) | 107 (60.1) | 131 (76.1) | 119 (70.0) | 121 (71.6) |
| 95% Cl, % (lower limit; upper limit) | (52.5; 67.4) | (69.1; 82.3) | (62.5; 76.8) | (64.2; 78.3) |
| Partial response | ||||
| n (%) | 5 (2.8) | 11 (6.4) | 10 (5.9) | 11 (6.5) |
| 95% Cl, % (lower limit; upper limit) | (0.9; 6.4) | (3.2; 11.2) | (2.9; 10.6) | (3.3; 11.4) |
| Stable disease | ||||
| n (%) | 2 (1.1) | 1 (0.6) | 2 (1.2) | 1 (0.6) |
| 95% Cl, % (lower limit; upper limit) | (0.1; 4.0) | (0.0; 3.2) | (0.1; 4.2) | (0.0; 3.2) |
| Progression under treatment* | ||||
| n (%) | 52 (29.2) | 20 (11.6) | 25 (14.7) | 16 (9.5) |
| 95% Cl, % (lower limit; upper limit) | (22.6; 36.5) | (7.2; 17.4) | (9.8; 20.9) | (5.5; 14.9) |
| Therapy-associated deaths without progression | ||||
| n (%) | 6 (3.4) | 5 (2.9) | 9 (5.3) | 13 (7.7) |
| 95% Cl, % (lower limit; upper limit) | (1.2; 7.2) | (1.0; 6.6) | (2.4; 9.8) | (4.2; 12.8) |
| Unknown | ||||
| n (%) | 0 (0.0) | 1 (0.6) | 2 (1.2) | 4 (2.4) |
| 95% Cl, % (lower limit; upper limit) | (0.0; 2.0) | (0.0; 3.2) | (0.1; 4.2) | (0.6; 6.0) |
| Additional therapy† | ||||
| n (%) | 6 (3.4) | 3 (1.8) | 3 (1.8) | 3 (1.8) |
| 95% Cl, % (lower limit; upper limit) | (1.2; 7.2) | (0.4; 5.0) | (0.4; 5.1) | (0.4; 5.1) |
| 3-year EFS | ||||
| % patients | 41.3 | 54.2 | 45.5 | 46.0 |
| 95% Cl, % (lower limit; upper limit) | (33.9; 48.6) | (46.6; 61.8) | (37.9; 53.2) | (38.3; 53.6) |
| 5-year EFS‡ | ||||
| % patients | 32.5 | 43.8 | 41.1 | 40.2 |
| 95% Cl, % (lower limit; upper limit) | (24.7; 40.3) | (35.4; 52.1) | (33.2; 48.9) | (32.2; 48.2) |
| 3-year overall survival | ||||
| % patients | 48.8 | 68.5 | 57.7 | 56.4 |
| 95% Cl, % (lower limit; upper limit) | (41.1; 56.4) | (61.3; 75.6) | (50.1; 65.3) | (48.6; 64.1) |
| 5-year overall survival‡ | ||||
| % patients | 40.6 | 53.3 | 45.8 | 49.8 |
| 95% Cl, % (lower limit; upper limit) | (32.5; 48.6) | (44.6; 62.1) | (37.4; 54.2) | (41.5; 58.0) |
Patient populations are as follows: CHOP-21, n = 178; CHOP-14, n = 172; CHOEP-21, n = 170; and CHOEP-14, n = 169. 95% Cl indicates 95% confidence interval.
Progression under treatment was defined as progressive disease during the treatment period or the time between the end of treatment until the first follow-up assessment after restaging, which was performed 2 months after the final restaging.
Patients in CR/CRu, but after receiving (additional off-protocol) treatment (eg, radiotherapy in the absence of bulky disease, more than 6 cycles of chemotherapy, or alternative treatment).
Estimated after a median time of observation of 58 months.